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ItalyHepatocellular carcinoma (HCC) is the third leading cause of cancer deathworldwide. Hepatocarcinogenesis is
a multistep process mainly associated with persistent infection with hepatitis B (HBV) or C (HCV) viruses and
always involving the accumulation of genetic alterations over decades of chronic liver disease. Mutations in
TP53 and CTNNB1 genes are considered the cancer drivers for HCC development with variable frequencies
depending on the etiology. Here we present a comprehensive review evaluating somatic mutations in TP53
and CTNNB1 genes in HBV- and HCV-related HCCs. Moreover, we report the mutational analysis of TP53
(exons 4–9) and CTNNB1 (exon 3) as well as PIK3CA (exon 9) genes in HCC from Southern Italy. The overall
mutation frequency of TP53 and CTNNB1 was 33.3%, while hotspot variations in PIK3CA were completely ab-
sent. CTNNB1mutations were signiﬁcantly associated with young age (P = 0.019) andmoderately/poorly dif-
ferentiated HCV-related HCC (P = 0.015). The extended analysis of genetic alterations will help to identify
molecular markers for liver cancer prevention, diagnosis and treatment of HBV and HCV-associated liver
cancer.
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Hepatocellular carcinoma (HCC), with 748,000 cases and 695,000
deaths in 2008, is the most common liver malignancy as well as the
third cause of death from cancer worldwide [1]. The regions of higher
incidence are Eastern and South-Eastern Asia as well as Middle and
Western Africa, with age standardized rates (ASR) ranging from 12.2
to 24.0 per 100,000 persons. In Europe, a remarkable North–South
geographic gradient has been observed, with ASRs ranging from 3.8
per 100,000 men in Northern to 9.8 per 100,000 men in Southern
Europe [1]. The highest incidence of HCC has been reported in men
living in Southern Italy with a peak of 34.8 cases per 100,000 in the
Campania region [2].
The majority of HCC cases are attributable to hepatitis B (HBV,
54%) and C (HCV, 31%) viruses, although a substantial geographic
variation exists in theworld. In Africa and Asia, where HBV is endemic,
more than 60% of liver cancers are related to HBV infection, 20% are
due to HCV and the remainder are caused by alcohol abuse and dietary
exposure to aﬂatoxins. Conversely, in the United States, Europe, Egypt
and Japan, more than 60% of HCCs are associated with HCV, 20% with
HBV and the rest are mainly attributable to excessive alcohol con-
sumption and liver metabolic diseases [3].
Both HBV and HCV, despite their distinct virologic features,
are preferentially hepatotropic, not directly cytopathic, able to sub-
vert the innate and adaptive immunity by several mechanisms and
persist long into hepatocytes [4,5]. Chronic infections give rise to a
complex, multistep process of hepatocarcinogenesis, lasting more
than 30 years, that encompass prolonged inﬂammation, hepatitis,
regeneration, ﬁbrosis, cirrhosis, dysplasia and ﬁnally HCC [6–8].
Cirrhosis is characterized by reduced hepatocyte proliferation, ﬁbro-
sis, destruction of liver cells and occurrence of dysplastic nodules
in around 15% of cirrhotic patients [9]. During this process the molec-
ular interaction between hepatitis viral products and the host cell
machinery, with or without other environmental factors, contributes
to the accumulation of a variety of genetic alterations which begin in
preneoplastic lesions and increase in dysplastic hepatocytes and HCC
[9]. Increased frequency of genetic damages may provide a progres-
sive selective growth advantage of hepatocytes with a malignant phe-
notype leading to the development of phenotypically and genetically
heterogeneous HCCs.
2. Chromosomal instability and genetic alterations in HBV- and
HCV-related liver cancer
Chromosomal aberrations and genome instability are more com-
mon in HBV than in HCV-related HCCs. Structural genetic alterations,
such as ampliﬁcations and deletions, develop slowly during chronic
hepatitis and increasingly in cirrhotic nodules and liver tumors [9].
Comparative genomic hybridization (CGH) and loss of heterozygosity
(LOH) analyses of HCC DNA have shown the occurrence of chromo-
somal instability in more than 80% of HBV-associated tumors. The
most distinctive events include gain of chromosomes 1q, 5, 6p, 7,
8q, 17q and 20; as well as loss of chromosomes 1p, 4q, 6q, 8p, 13q,
16, 17p and 21 [9–12]. The gain of 8q24 locus copy number, together
with overexpression of c-Myc located on this region, has been signif-
icantly associated with HBV, HCV, and alcohol abuse but not with
cryptogenic HCCs [13], suggesting that liver tumors can be classiﬁed
in genetically homogeneous subclasses with different etiologies.
HBV sequences are found often integrated into the DNA of HCC
as well as non-cancerous liver cells of chronic HBV carriers in asso-
ciations with several genetic alterations [14–17]. Whole-genome
deep sequencing showed that HCCs harbored large numbers of
clonally-integrated HBV genomes, while autologous non-tumor tis-
sues contained low-frequency viral integration sites scattered across
the human genome, indicating that such events occur during the
early stage of tumorigenesis [18]. HBV integration is accompaniedby altered expression of human genes located near the integration
sites, by formation of viral–human fusion genes, and changes in DNA
copy number possibly introduced by genomic instability at viral–
human junctions. Independent studies have reported recurrent HBV
integrations within or upstream of the telomerase reverse transcrip-
tase (TERT) gene in several HCC cases [19,20]. Other recurrent integra-
tion sites were found to affect cellular genes, such as FAR2, ITPR1,
IRAK2, MAPK1, MLL2 and MLL4 genes, potentially providing cell
growth advantages [20–24]. Recently, Sung et al. reported that HBV
integration breakpoints frequently affect the 1800-bp region
containing the viral enhancer, the X gene and the core gene [20].
This breakpoint usage may facilitate the formation of chimeric viral–
human fusion genes, corrupting cellular tumor suppressors or imposing
cis-regulatory effects on the expression of downstream cellular genes.
Moreover, among 26 pairs of HCC and normal tissue samples having
integrated HBV, only one breakpoint was shared between pairs of
tumor and non-tumor DNAs [20]. These results strongly support the
hypothesis that HBV contributes to the hepatocarcinogenesis by intro-
ducing numerous genetic lesions in different hepatocytes, some of
which determine structural and functional alterations of genes relevant
for cell cycle control.
HCV-related pathogenic processes, leading to viral cirrhosis and
HCC, are much less known [25]. HCV is a completely cytoplasmic-
replicating virus, maintaining its genome as an episome associated
with endoplasmic reticulum. HCV causes chronic hepatitis in more
than 80% of infected subjects, versus the 10% persistence of HBV
infected patients, and it is 10 to 20-fold more efﬁcient than HBV in
promoting liver cirrhosis [5]. HCV pathogenic activity has been related
mainly to the core protein and the non-structural proteins NS3
and NS5A, which are able to promote cell survival and growth, and
contribute to the oncogenic transformation of infected hepatocytes
[26]. Moreover, HCV proteins may concur indirectly to the genetic
instability of infected cells through the suppression of DNA repair
mechanisms, induction of DNA breaks, enhancement of the mutation
frequency and chromosome rearrangements [27]. The non-structural
HCV protein NS3 has both protease and helicase activities, which can
directly contribute to genomic instability [28].
3. Mutations of tumor suppressor genes and oncogenes in
HBV- and HCV-related hepatocellular carcinoma
During the past 20 years signiﬁcant efforts have been made to de-
ﬁne the patterns of somatic mutations affecting key pathways in HBV-
and HCV-associated liver tumors. In particular, non-synonymous
nucleotide changes have been commonly detected in TP53 (above
30%), CTNNB1 (19%) and AXIN1 (14%) genes, while homozygous dele-
tions and epigenetic silencing have been identiﬁed in CDKN2A and
CDKN2A alternate open reading frames (11.5%). More recently the
application of new powerful tools, such as whole-genome or exome
sequencing analysis, has conﬁrmed most of previously known muta-
tions in TP53 and CTNNB1 genes in HCC but also identiﬁed novel
genetic alterations in genes critical for cell proliferation and tumor
development [29]. According to the Catalog of Somatic Mutations in
Cancer (COSMIC), four tumor suppressor genes (TP53, ARID1A, AXIN1
and CDKN2A) and one oncogene (CTNNB1) are mutated in more than
10% of the tumors, whereas several other genes are less frequently
altered (Fig. 1), [30]. In particular, among mutated tumor suppressor
genes ARID1A, encoding for a chromatin remodeling SWI/SNF complex
component, was recently shown to be inactivated in several tumor
types, including gastric, ovarian and bladder carcinoma, but its in-
volvement in HCC was not known before the application of next gen-
eration technologies [31]. Recurrent somatic mutations in ARID1A and
ARID2 genes have been found in 16.8% and 5.6% of HCC cases, respec-
tively [10]. ARID1Amutations were signiﬁcantly more frequent in HCC
related to alcohol intake (P = 0.002) than in tumors of other etiolo-
gies and showed a signiﬁcant association with CTNNB1 mutations;
Fig. 1.Mutation frequencies of tumor suppressor genes and oncogenes in HCC as anno-
tated in the COSMIC database or reported in recently published reports.
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polybromo- and Brg1-associated factor (PBAF) complex, were less fre-
quent but exclusive from ARID1Amutations (P = 0.05) [10]. Fujimoto
et al. reported an overall mutation frequency of 50% in chromatin
regulator encoding genes, including ARID1A, ARID1B, ARID2, MLL
and MLL3, in HCC associated with hepatitis B or C virus infections.
This observation is consistent with the high heterogeneity of genetic
alterations in liver cancer resulting from aberrations in chromatin
remodeling.
3.1. The spectrumofmutations in TP53 gene inHBV- andHVC-relatedHCCs
Mutations in the TP53 tumor suppressor gene are among the most
common genetic alterations in many human malignancies including
liver cancer [32–36]. Up to 90% of TP53mutations are non-synonymous
and determine single amino-acid changes primarily within the DNA
binding domain region located between codons 125 and 300 [37].
Amino acid substitutions in the p53 protein often affect its tertiary struc-
ture resulting in a stable protein with increased half-life and reduced
DNA-binding activity [38]. A mutated p53 protein may inactivate
wild-type p53 proteins via the formation of mutant and wild-type
dimeric structures which in turn prevent the formation of functional
tetramers [39–41]. Moreover several p53 mutants acquire ex novo
pro-oncogenic properties, deﬁned as “gain of function”, which include
enhanced cell proliferation, resistance to drugs, increased cell migration
and invasion as well as promotion of neo-angiogenesis [42–46].
Several studies have demonstrated a link between exposure to
speciﬁc carcinogens, induction of deﬁnite mutational events within
the TP53 gene and development of speciﬁc cancers, leading to the no-
tion of “mutagen ﬁngerprints” [47,48]. Among these signatures the
well documented associations are: 1) exposure to ultraviolet irradia-
tion with tandem CC to TT transitions in non-melanoma skin cancers
[49]; 2) tobacco smoking derived polycyclic aromatic hydrocarbons
with G to T transversions at speciﬁc G:C base pairs of TP53 gene in
lung cancer [50,51]; 3) dietary exposure to aristolochic acid with A
to T mutation in Balkan endemic nephropathy [52]; 4) and most
prominently the dietary exposure to aﬂatoxin B1 (AFB1) with G to
T transversion at the third base of codon 249 (AGG to AGT) in liver
tumors [53,54].
Up to 50% of HCC, from geographic regions with dietary exposure
to AFB1 and high prevalence of HBV infection, contains G to T muta-
tions at codon 249 (arginine to serine, R249S) of TP53 gene [55]. A re-
cent study conducted in Thailand showed that TP53 R249S mutation
occurs preferentially in liver tumors that develop in a context of HBV
infection without concomitant liver cirrhosis, suggesting that TP53R249S represents one of the critical hit in the development of liver
cancer [56]. Importantly, the TP53 R249S can also be detected in circu-
lating free DNA from patients with HCC, so that TP53mutant DNAmay
be a biomarker of exposure to AFB1 and possibly early diagnosis of
HCC [57]. It has been hypothesized that AFB1-induced TP53 R249S
mutation is an early event in the hepatocarcinogenesis process and
HBV chronic infection has a multiplicative effect on the risk of HCC
[58]. Laboratory studies have shown that the synergistic effect be-
tween HBV and AFB1 may depend on the ability of the p53 protein,
either wild-type or mutant, to interact with HBx viral protein [59].
The mutated protein p53 R249S, in fact, is able to form stable com-
plexes with the viral oncoprotein HBx and to exert tumor promoting
activities in infected hepatocytes. HBx, on the other hand, has been
shown to enhance HBV replication and to exert multiple effects on a
wide range of host factors involved in apoptosis, cell proliferation
and DNA repair [60,61]. In addition, TP53 mutations in HBV-related
HCC, particularly the hot spot mutations at codons 249 and 157,
have been associated with the acquisition of the stem cell-like pheno-
type, tumor aggressiveness and poor prognosis [62].
In geographic regions with low dietary exposure to AFB1 codon
249 is rarely affected and, instead, a variety of somatic mutations in
TP53 gene may occur as a late event in liver carcinogenesis [63,64].
This hypothesis is supported by the appearance of dedifferentiated
cellular subpopulations following the occurrence of TP53 mutations
within HCC [65], the occurrence of distinct mutations in nodule-in-
nodule HCCs [66], presence of more severe cellular atypia in areas
with LOH of TP53 within HCC [64], and ﬁnally the high rate of TP53
mutations in moderately to poorly differentiated HCC [67]. Moreover,
the spectrum of TP53 mutations is very wide with 75% missense
mutations scattered over 200 codons mainly throughout the central
portion of the gene affecting the central DNA-binding domain of the
encoded protein [35,37].
To identify speciﬁc patterns of TP53 nucleotide changes in HCC as-
sociated with different etiologies, we have reviewed data annotated
in the TP53 database (http://www-p53.iarc.fr/) of the International
Agency for Research on Cancer (IARC) and the COSMIC database
(http://www.sanger.ac.uk/genetics/CGP/cosmic/). All TP53 mutations
identiﬁed in HCC samples were stratiﬁed according to HBV, HCV,
AFB1-induced R249S TP53 status and geographical origin (Africa,
Americas, Asia and Europe). As shown in Fig. 2, we observed an overall
TP53mutation rate signiﬁcantly higher in Africa (35.1%), Asia (31.6%)
and Europe (25.2%) than Americas (11.4%), (P b 0.0001). More than
18% of African HCC samples were mutated at codon 249 in TP53 gene
conﬁrming that a high proportion of mutations in African regions
are due to AFB1 exposure. In order to evaluate the frequency of TP53
mutations not associated to AFB1, we have excluded HCC samples
with the TP53 R249S mutation and then stratiﬁed the remaining
tumors by etiology and geographical origin. Among HBV-related and
TP53 R249S-unrelated HCCs we observed a high mutation frequency
in Asia (23.2%) and Europe (24.5%) and a lower frequency in Africa
(6.25%), consistent with the preponderant role of AFB1 in HBV-
related liver tumorigenesis in African regions. In HCV-related and
TP53 R249S-unrelated HCC, on the other hand, TP53 mutations were
similarly frequent in Africa (24.2%), Asia (25.3%) and Europe (27.6%),
suggesting a minor effect of AFB1 in the development of liver cancer
associated with HCV infection.
The analysis of mutated nucleotides in TP53 gene showed that more
than 60% of nucleotide changes were localized in non-transcribed
strand in both HBV- and HCV-related HCCs, suggesting that a strand
bias occurred during the mutation process probably due to the prefer-
ential repair of the transcribed DNA during transcription-coupled repair
[68]. Moreover, the nucleotide change G to A and themirror transition C
to T were more abundant in HCV-related (36%) than in HBV-related
HCC (25%) (Fig. 3). The G to A transition may result from deamination
of methylated cytosines at CpG sites originating from spontaneous
deamination of 5-methylcytosine into thymine [69]. This process is
Fig. 2. Frequency of TP53 mutations in all HCCs (% TP53 mut) stratiﬁed by HBV (as percentage of all HBV-related R249S–unrelated HCC: % HBV TP53 mut) and HCV (as percentage
of all HCV-related R249S–unrelated HCC: % HCV TP53 mut) status as well as by AFB1-induced R249S mutation. Cases associated with unspeciﬁed hepatitis virus and of unknown
etiology have been grouped in the undetermined (as percentage of all undeﬁned and R249S–unrelated HCC: % und TP53mut) group. HBV and HCV double infections were included
in the HBV group.
77M.L. Tornesello et al. / Genomics 102 (2013) 74–83enhanced by oxygen and nitrogen radicals, leading to a higher load of
CpG transitions in cancers arising from inﬂammatory precursors such
as Barrett's mucosa or ulcerative colitis [70–74]. Chronic inﬂammationFig. 3. Mutational patterns of TP53 gene in HBV- and HCV-related HCCs from different ge
etiology have been grouped in the undetermined (% und CTNNB1 mut) group.and the generation of an excess reactive oxygen species, which causes
oxidative DNA damage or increases susceptibility to the acquisition of
somatic mutations, may be responsible for the larger proportion ofographical regions. Cases associated with unspeciﬁed hepatitis virus and of unknown
78 M.L. Tornesello et al. / Genomics 102 (2013) 74–83TP53mutations accumulating in HCV-related cancer [75]. Free radicals,
in fact, reactive nitrogen or oxygen species, have been demonstrated to
directly damage DNA and proteins, and indirectly perturb these macro-
molecules via lipid peroxidation in the formation of DNA repair protein
complexes and transcriptional transactivation of DNA repair genes
[76]. Nucleotide changes G to T (at sites other than codon 249) and C
to A were found more frequently in HBV-related HCC (29%) than
in HCV-related HCC (19%). As shown in Fig. 3, following geographical
stratiﬁcation, G>T transversion frequency remained higher in HBV-
positive HCC (36% of all mutations in Americas and Europe; 28% in
Africa and Asia) compared to HCV-positive tumors (11% Americas and
Europe; 18% in Africa and Asia). The nucleotide changes A to T and T
to A were also relatively frequent among African and Asian samples
(20% in HBV-positive; 22% in HCV-positive), suggesting a possible
genotoxic effect of agents such as vinyl chloride which has been
shown to induce A to T transversion in animal models [77].
The effect of TP53 mutations on pathway deregulation has been
studied by microarray analysis of genes differentially expressed in
HCC with mutant or wild type TP53 gene. Okada et al. found 83 differ-
entially expressed genes in TP53 mutant compared with wild type
TP53 HCCs [78]. Among these genes, overexpression was described
for cell cycle-related genes (CCNG2, BZW1) and cell proliferation-
related genes (SSR1, ANXA2, S100A10, and PTMA). These results to-
gether with data demonstrating that p53 mutations constitute an
unfavorable prognostic factor, related to recurrence in HCC, suggest
that mutant p53 tumors may have higher malignant potentials than
those with wild type p53 [62,79].
3.2. CTNNB1 mutations in hepatocellular carcinoma
β-Catenin, encoded by CTNNB1 gene, is a crucial element of the ca-
nonical Wnt signaling pathway [80]. In the absence of Wnt, cytoplas-
mic β-catenin protein is phosphorylated at the N-terminal domain
(serine 33, 37 and 45, threonine 41) by the Axin complex (composed
of Axin, APC, CK1, and GSK3) and then ubiquitinated and degraded by
β-Trcp ubiquitin ligase [81]. Activation of Wnt signaling induces the
stabilization and translocation of β-catenin to the nucleus, where it
associates with transcription factors of the TCF family and generates
a functional complex able to transactivate several genes (MYC,
CCND1,MT-CO2, andMMP7) involved in the cell cycle control and pro-
liferation [82,83].
Aberrant activation of Wnt signaling and nuclear accumulation of
β-catenin has been reported in several types of cancer, including HCC
[84]. The most common mechanisms of β-catenin increase in HCC are
mutations in CTNNB1 gene, identiﬁed in about 20–40% of liver cancers
[85–87], and mutations in genes encoding for the components of
the degradation complex of β-catenin including AXIN1 (3–16%)
[75,173,175,176], and AXIN2 (3%) genes [86,88]. Most CTNNB1 muta-
tions occur within the exon 3 of the gene, in a region encoding for the
protein sequence containing the consensus sites for phosphorylation.
Mutation of serine/threonine residues results in impaired Axin/APC/
GSK3b mediated degradation of β-catenin and gain of oncogenic ac-
tivity [89]. Several studies demonstrated a critical role of β-catenin
mutations in hepatocarcinogenesis. In particular, CTNNB1 mutations
are found to be associated with increased levels of glutamine synthe-
tase, higher macrovascular and microvascular invasions and tumor
size increase [90]. Moreover, Wnt/β-catenin signaling has shown to
play an important role in oval cell activation, considered to be hepatic
stem cells, and HCCs with stem cell signatures are shown to have a
more aggressive behavior [91,92]. However the clinical implications
of CTNNB1missensemutations in terms of overall survival and disease
recurrence have not yet been comprehensively evaluated.
Whole genome sequencing studies conﬁrmed previous analyses
showing that CTNNB1 is the most frequently mutated oncogene in
HCCs [18]. Interestingly, a high frequency of CTNNB1 mutations has
been shown in HCCs occurring in HCV-positive patients [10,19,93].In particular, Guichard et al. analyzed the spectrum of mutations in
CTNNB1, TP53 and several previously uncharacterized genes in HCC
samples from a cohort of French patients [10]. They observed that
CTNNB1 mutations were present in 11.4% of HBV-associated HCC, in
33.3% of HCV-related HCC and in 41.8% of alcohol-related HCCs [10].
Although CTNNB1 gene has been found mutated at lower frequency
in HBV-positive tumors, it has been demonstrated that the Wnt/
β-catenin pathway is always perturbed in HBV-related tumors by
the direct action of HBx protein which decreases proteasomal degra-
dation of β-catenin [94,95]. Interestingly mutations of CTNNB1and
TP53 gene appear to be largely mutually exclusive, suggesting that
inactivation of either pathway is sufﬁcient to induce cellular transfor-
mation [10]. Moreover, HCCs characterized by activation of Wnt/
β-catenin pathway exhibit speciﬁc features such as high differentia-
tion associated with a homogeneous microtrabeculo-acinar pattern,
low-grade cellular atypia, and cholestasis [96]. These ﬁndings demon-
strate an essential role of the Wnt signaling in hepatocarcinogenesis
and suggest that targeting this pathway may be promising for thera-
peutic options.
We have differentiated the CTNNB1mutations annotated in COSMIC
database according to HBV and HCV status and to geographical origin
(Africa, Americas, Asia and Europe). As shown in Fig. 4, we observe an
overall CTNNB1 mutation rate higher in Europe (25.2%) and Americas
(21.8%) than Asia (15.9%). The single study performed in Northern
Africa showed only 4 mutated cases in 42 (9.5%) HCCs. Among
HCV-related HCC, CTNNB1 mutations were similarly distributed in
HCC from Asia (28.3%) America (25.6%) and Europe (23.6%), suggesting
the absence of an exogenous genotoxic factor diversely distributed in
different geographic regions. On the other hand, frequency of CTNNB1
mutations in HBV-related HCCs is equal or below 10% in all studied
regions (Asia 9.2%, America 10% and Europe 6.8%) with exception of
Africa where stratiﬁcation by hepatitis virus was not available.
During the last 10 years, microarray technology enabled the
analysis of global gene expression in a large number of HCCs and
the identiﬁcation of tumorswith speciﬁc signatures of pathway dereg-
ulation, including those speciﬁcally associated to CTNNB1 mutations
[91,97–100]. Boyault et al. performed an unsupervised transcriptomic
proﬁle along with genetic analysis in 60 HCCs and they identiﬁed
six subgroups of tumors (termed G1 to G6) with distinct clinical
and genetic characteristics [101]. HCCs from groups G1 to G3 were
chromosome instable whereas tumors from groups G4 to G6 were
chromosome stable [101]. Interestingly, HCCs falling into G5 and G6
were highlymutated in CTNNB1 gene andWnt pathwaywas activated.
Tumors of G6 group, characterized by satellite nodules, show the
higher activation of the Wnt pathway and E-cadherin underexpression
[101].
Finally, mutations in CTNNB1 genes have been associated to down-
regulation of miR-107, a small non-coding RNAs, which modulates
the HNF1α gene involved in β-catenin regulation via downregulation
ofmiR-375 [102]. Hence, liver tumors showalso distinctmiRNA expres-
sion ﬁngerprints according to malignancy, risk factors as well as muta-
tions in oncogenes and tumor suppressor genes.
3.3. PIK3CA gene mutation in HCC
Controversial reports have been published on the presence of
somatic mutations in the exon 9 of phosphoinositide-3-kinase-
catalytic-alpha (PIK3CA) gene. The PIK3CA gene has been found mu-
tated in approximately 35.6% of HCC cases in China [103], in 28% of
HCC in Italy [104] and in zero cases of HCC in Japan [105]. PIK3CA
is an effector of the phosphatase and tensin homolog (PTEN)–AKT
pathway affecting cell proliferation, apoptosis and angiogenesis.
Knowledge ofmutational status of PIK3CA gene is particularly relevant
considering that several anticancer drugs, targeting PI3K/Akt path-
way, have given promising preliminary results in humanmalignancies
[106]. However, few studies have been conducted to evaluate the
Fig. 4. Frequency of CTNNB1 mutations in HCCs stratiﬁed by HBV (% HBV CTNNB1 mut) and HCV (% HCV CTNNB1 mut) status and geographic origin. HCC cases not related to viral
infection or of unknown etiology have been assembled into the undetermined (% und CTNNB1 mut) group.
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in different regions of the world and no clear conclusion can be drawn
on the role of such gene in liver cancer.
4. TP53, CTNNB1 and PIK3CA gene mutation in HCC from
Southern Italy
In the province of Naples (Southern Italy) 23.2% of men aged
65 years or older are HCV-positive and 61% of HCC cases are attribut-
able to HCV infection [107,108]. Liver cancer develops in 1% to 3% of
HCV-positive subjects in 20–30 years after they become infected,
suggesting that besides HCV other factors may contribute to tumori-
genesis [109–111]. We have evaluated the mutation frequency of
TP53 (exons 5–8), CTNNB1 (exons 3) and PIK3CA (exon 9) genes in
a series of HCV- and HBV-positive cases diagnosed with hepatocellu-
lar carcinoma from people living in the province of Naples.Table 1
Distribution of mutations in TP53 and CTNNB1 genes according to the characteristics of
HCC Patients.
Characteristics TP53 CTNNB1
No Mut % P No Mut % P
Sex
Male (n = 53) 8 15.1 0.686 9 16.7 0.675
Female (n = 14) 3 21.4 1 7.1
Age
≤60 (n = 13) 3 23.1 0.473 5 30.8 0.019
>60 (n = 54) 8 14.8 5 9.3
Grading⁎
G1 (n = 2) 0 0.614 0 0.015
G2 (n = 57) 9 15.8 6 10.5
G3 (n = 8) 2 25.0 4 37.5
pT
pT1 (n = 8) 1 12.5 0.912 1 12.5 0.979
pT2 (n = 33) 6 18.2 5 12.1
pT3 (n = 26) 4 15.4 4 15.4
No Tumor sites
Single (n = 41) 7 17.1 0.856 4 11.1 0.169
Multiple (n = 26) 4 15.4 6 12.9
Virus
HBV (n = 10) 2 20.0 0.742 0 0.337
HCV (n = 57) 9 15.8 10 17.5
⁎ Well differentiated (G1); Moderately differentiated (G2); Poorly differentiated
carcinoma(G3).Liver samples from patients with primary HCC (n = 67) and cir-
rhosis (n = 10) were analyzed for TP53, CTNNB1 and PIK3CA muta-
tions. Gender, viral infection and tumor differentiation are described
in Table 1. The majority of patients were males (78.7%), and the mean
ages were 66.3 ± 9.3 (range 39–85) and 74.4 ± 7.3 (range 61–87)
for males and females, respectively. The greater number of cases was
HCV-positive cirrhotic patients with HCC.
The TP53 gene was altered in 9 out of 57 (15.8%) HCV-positive and
in two out of 10 (20%) HBV-positive HCC cases. The most common
nucleotide changes were missense mutations (n = 10) and in one
case there was a single nucleotide deletion creating a frameshift
(Table 2). The AFB1-related G to T transversion at codon 249 was
not detected in any HCC sample.
Ten out of 57 (17.5%) HCV-positive and none of the HBV-positive
HCC cases harbored nucleotide changes in CTNNB1 gene. Six mutations
affected serine residues (Ser33, Ser37 and Ser45) (Fig. 5). No insertion
or deletions were detected. CTNNB1 mutations were signiﬁcantlyTable 2
TP53 and CTNNB1 mutations are mutually exclusive in hepatocellular carcinomas.
ID Grade Etiology TP53 mutation CTNNB1 mutation
LC-137 G2 HBV 134, TTT>TTA Phe>Leu;
275 TGT>TAT Cys>Tyr
LC-159 G2 HBV 274, GTT>GTG
LC-061 G3 HCV 245, GGC>GTC Gly>Val
LC-132 G2 HCV 232, ATC>AAC Ile>Asn
LC-153 G2 HCV 226, Delta G (GGC>GC)
LC-156 G2 HCV 137, CTG>CTA;
282 CGG>TGG Arg>Trp
LC-180 G2 HCV 220, TAT>CAT Tyr>His
LC-181 G2 HCV 208, GAC>GTC Asp>Val
LC-187 G2 HCV 245, GGC>GAC Gly>Asp
LC-226 G2 HCV 311, AAC>AGC Asn>Ser
LC-237 G2 HCV 245, GGC>GAC Gly>Asp
LC-064 G3 HCV 35, ATC (Ile)>AGC (Ser)
LC-117 G3 HCV 37, TCT (Ser)>TTT (Phe)
LC-129 G2 HCV 37, TCT (Ser)>TAT (Tyr)
LC-138 G2 HCV 45, TCT (Ser)>CCT (Pro)
LC-144 G2 HCV 34, GGA (Gly)>GAA (Glu)
LC-177 G3 HCV 33, TCT (Ser)>TGT (Cys)
LC-208 G2 HCV 33, TCT (Ser)>GCT (Ala)
LC-212 G2 HCV 34, GGA (Gly)>GTA (Val)
LC-225 G3 HCV 37, TCT (Ser)>TTT (Phe)
LC-235 G2 HCV 32, GAC (Asp)>CAC (His)
Fig. 5. DNA sequence electropherograms showing nucleotide mutations in exon 3 of CTNNB1 gene at codons that encode serine residues (Ser33, Ser37 and Ser45). All mutations
have been identiﬁed in genomic DNA from HCV-positive Italian HCC samples.
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HCC histotype (P = 0.015).
The combined mutational pattern of CTNNB1 and TP53 genes
showed that relevant proportions of nucleotide changes were
C:G>T:A transitions (33%), A:T>G:C transitions (17%) and A:T>T:A
transversions (17%) potentially arising from deamination of DNA
bases. The other mutations were A:T>C:G (17%), C:G>A:T (12%)
and C:G>G:C mutations (12%).
The exon 9 of PIK3CA gene was mutated at codon 518 (ACT>GCT,
Ala>Thr) only in one out of 67 (1.5%) HCCs. Moreover, a rare synony-
mous polymorphism in PIK3CA gene at codon 495 (rs45455192,
TCC>TCT, Ser/Ser) was observed with T/T homozygous (1.5%), C/T
heterozygous (14.9%) and C/C homozygous (83.6%) genotypes of all
analyzed liver tissues. There was no statistical signiﬁcant difference
in the frequency of this polymorphism between HCCs with different
characteristics.
No mutations in TP53, CTNNB1 and PIK3CA genes were detected in
DNA samples extracted from cirrhotic tissues.
5. Conclusions
There are two main etiological types of HCC, heterogeneously
distributed in different geographical regions, owing to HBV or HCV in-
fection [3]. Several studies have explored the molecular differences
between them. The analysis of public available databases showed
that TP53 mutations could be deﬁned as the cancer drivers for both
HBV-related and HCV-related HCCs due to the high mutation fre-
quency of this tumor suppressor gene in the two types of tumors.
In low-resource regions (mainly in Africa and Asia) AFB1 exposure
represent the main genotoxic factors for TP53 R249S mutation and
development of HCC in association with HBV infection. Mutations in
CTNNB1 gene, on the other hand, are similarly frequent in HCV-related
and non-viral related HCCs from different geographic regions, while
are underrepresented in HBV-associated tumors.
The results obtained in our Italian HCC series show that somatic
mutations in TP53 gene are similarly represented in HBV- (20%) and
HCV-related (15.8%) HCC cases and comparable to that previously
reported among HCC cases from Northern Italy (25%) and France
(18%) [112]. Moreover, TP53 mutations were similarly distributedamong the different patient groups, and no statistically signiﬁcant
correlation with sex, onset age and histological tumor grading was
found. We observed no mutations at hot spot codons 249 indicating
that AFB1 is not a relevant carcinogenic agent in HCC for patients
from Southern Italy.
In agreementwith the previous report [10], we found thatmutations
in exon 3 of CTNNB1gene occurred exclusively in HCV-related HCCs
(17.5%). All mutations were heterozygous, located between codon 32
and codon 45, and mutually exclusive with mutations in TP53 gene.
The proportion of activatingmutations in CTNNB1 genewas signiﬁcant-
ly lower compared to that observed among French HCC cases [10]. The
lower mutation frequencymay be due to the fact that all cases analyzed
in our studywere cirrhotic HCCs and CTNNB1mutationswere described
to be particularly prevalent in non-cirrhotic HCC patients [90]. On the
other hand, non-cirrhotic HCC are rarely found in the Italian population
representing less than 2% of HCC cases [111]. A relevant observation
from our study was that patients with HCC mutated in CTNNB1 gene
were signiﬁcantly younger or with moderately/poorly differentiated
tumors compared to patients with wild-type CTNNB1.
Hot spot mutations in the exon 9 of PIK3CA were found in none
of the HCC samples. This observation is in agreement with previous
studies performed in HCC series from Japan and France showing
that mutations in PIK3CA are rare and likely not a key event in
liver carcinogenesis [10,105]. The controversial results concerning
the high frequency of mutations in exon 9 of PIK3CA gene in HCC sam-
ples from China [103] and Southern Italy [104] might partially be
explained by the confounding effect of PIK3CA pseudogene sequences
located on chromosome 22 and sharing 98% homology with PIK3CA
exon 9 [105,113]. The GT to C mutation at nucleotides 1658–1659
described in 15% of HCC by Colombino et al., was identiﬁed in 27.7%
of HCC and autologous noncancerous liver by Tanaka et al. and
shown to be a PIK3CA pseudogene sequence [105]. Therefore, particu-
lar attention should be paid on the interpretation of data related to hot
spot mutations in PIK3CA gene.
In conclusion, our analysis suggests that TP53 and CTNNB1 genes
together contribute to deﬁne distinct subgroups of viral-related HCC.
Further studies will be needed to deﬁne whether stratiﬁcation of
HCC patients by TP53 and CTNNB1mutational status might be predic-
tive of prognosis and relevant for patient tailored therapy.
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6.1. Patient and tissue samples
Liver biopsies from 57 HCV-positive, 10 HBV-positive, along with
10 cirrhotic liver tissue samples were obtained with informed con-
sent from patients treated at the liver unit of the INT “Pascale” in
Naples. Patients were classiﬁed according to Child–Pugh score into
A (n = 56), B (n = 9) and C (n = 2). Tumor size and number of
tumor nodules were determined by routine imaging (i.e., computed
tomography or magnetic resonance imaging). Each liver biopsy was
divided in two sections: the ﬁrst section was stored in RNA Later
at −80 °C (Ambion, Austin, TX), the second was subjected to histo-
pathologic examination. Only liver biopsies histological conﬁrmed
to be hepatocellular carcinoma or cirrhotic tissue were included in
the study.
The 67 HCCs were divided into three groups according to their
histological grade: well differentiated (G1) HCC (n = 2), moderately
differentiated (G2) HCC (n = 57) and poorly differentiated (G3) HCC
(n = 8) according to the criteria of Edmondson and Steiner [114].
Genomic DNA was extracted according to published procedures
[115]. Tissue samples were digested by proteinase K treatment
(150 μg/ml at 56 °C for 2 h) in 100–500 μl of lysis buffer (10 mM
Tris–HCl, pH 7.6, 5 mM EDTA, 150 mM NaCl, 1% SDS), followed by
DNA puriﬁcation with phenol–chloroform–isoamyl alcohol (25:24:1)
extraction and ethanol precipitation in 0.3 M sodium acetate (pH 4.6).
The study protocol was approved by the local ethical review board.
6.2. TP53 codon 4–9 mutational analysis
The analysis of TP53 gene in exons 4–9 was performed using speciﬁc
oligonucleotides and ampliﬁcation protocols according to the IARC
guidelines (http://www-p53.iarc.fr/Download/TP53_DirectSequencing_
IARC.pdf). All PCR reactions were undertaken using 10 to 100 ng geno-
mic DNA in 50-μl reaction mixture following the IARC ampliﬁcation
procedures. All samples with sufﬁcient amount of DNA were subjected
to bidirectional direct sequencing analysis by Primm Srl Laboratories
(Milan, Italy).
6.3. CTNNB1 codon 3 and PIK3CA codon 9 mutational analysis
CTNNB1 exon 3 was ampliﬁed using the oligoprimers Beta-F
(5′-CCAATCTACTAA TGCTAATACTG-3′) and Beta-R (5′-GCATTCTGAC
TTTCAGTAA GGC-3′) able to generate a 310 bp fragment which covers
hot spot codons 33, 37, 41 and 45. PIK3CA codon 9 was ampliﬁed
using the oligoprimers PIK3-9-F1 (5′-TGGTCTTGTT GTTGGCTAA) and
PIK3-9-R1 (5′-CTTACCTGTGACTCCATAGAA) generating a 410 bp frag-
ment encompassing the hot spot codons 542 and 545 and designed
to avoid ampliﬁcation of the PIK3CA pseudogene. PCR reactions were
performed in 50 μl reaction mixture containing 50 to 100 ng of target
DNA, 5 pmol of each primer, 2.5 mMMgCl2, 50 mM of each dNTP and
5 μl Hot Master buffer and 1 U of Hot Master Taq DNA Polymerase
(5 Prime GmbH, Hamburg, Germany). DNA was ampliﬁed in a Perkin-
Elmer GeneAmp PCR System 9700 thermal cycler with the following
steps: an initial 1-min denaturation at 94 °C, followed by 45 ampliﬁca-
tion cycles of 58 °C for 30 s, 72 °C for 30 s, 94 °C for 30 s and a 1-min
ﬁnal annealing at 58 °C followed by 5-min elongation at 72 °C. All
samples were subjected to bidirectional direct sequencing analysis.
6.4. Statistical analyses
A Fisher's exact test or Yates corrected χ2 test was used, as appro-
priate, to compare the proportions of cases mutated in TP53 or
CTNNB1 genes among patients stratiﬁed by sex, age, tumor grading
and hepatitis virus infection. All analyses were performed with Epi
Info 6 Statistical Analysis System Software (6.04d, 2001, Centers forDisease Control and Prevention, USA). Differences were considered
to be statistically signiﬁcant when P values were less than 0.05.
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